Gossamer Bio, Inc. announced on September 16, 2026, that Gregory A. Ciongoli has been appointed to the company’s Board of Directors, effective immediately. Mr. Ciongoli will serve as a Class III director with an initial term expiring at the Company’s 2027 annual meeting of stockholders. He has also been appointed to the Audit Committee.
Mr. Ciongoli, age 51, is the Founder and Managing Partner of Adiumentum Capital Management, a Boston-based investment firm, a role he has held since April 2024. Prior to founding Adiumentum, he served as a Partner at the Baupost Group from 2007 to 2024. He currently serves on the boards of directors of REGENXBIO Inc., Zymeworks, Inc., and Atara Biotherapeutics, Inc., where he has served as Chair of the Board since September 2025. Mr. Ciongoli holds an A.B. from Princeton University and an M.B.A. from Harvard Business School.
According to the filing, Mr. Ciongoli will receive an annual cash retainer of $40,000 for service on the Board and an additional $7,500 for service on the Audit Committee. He is also entitled to equity compensation under the Company’s non-employee director compensation program. The Board determined that a standard initial equity award will be made at a future date and in a future amount to be determined by the Board.
The filing notes that Mr. Ciongoli is an independent director in accordance with the listing requirements of the Nasdaq Global Select Market. It also references a private placement transaction closed on August 24, 2026, in which Mr. Ciongoli participated as a purchaser, acquiring warrants related to the transaction. The Board has determined that there is no arrangement or understanding between Mr. Ciongoli and any other person regarding his appointment.
